Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion

Molecular Pharmacology
Lukmanee TradtrantipA S Verkman

Abstract

We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecar...Continue Reading

References

Oct 1, 1992·Pathology·D H BarklaI P Hayward
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R Mangoo-KarimJ J Grantham
Oct 1, 1993·The American Journal of Physiology·K E Barrett
Mar 14, 2000·Archives of Medical Research·M MurakamiM Mori
Mar 15, 2003·The Journal of Biological Chemistry·Peter R WielingaPiet Borst
Apr 3, 2003·The Journal of Clinical Investigation·Michael Field
Aug 23, 2003·Circulation Research·Sergei D RybalkinJoseph A Beavo
Jan 24, 2004·Lancet·David A SackA K Siddique
Apr 6, 2005·Trends in Pharmacological Sciences·Jay R Thiagarajah, A S Verkman
Aug 11, 2005·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·G MeyerM Paulmichl
Feb 8, 2006·Annual Review of Physiology·Karnam S Murthy
Feb 24, 2006·Infection and Immunity·John K CraneMichael E Duffey
Apr 4, 2006·Cell Cycle·W C G van StaverenC Maenhaut
Jun 13, 2006·Cell and Tissue Research·William E Sweeney, Ellis D Avner
Sep 14, 2006·Pharmacological Reviews·Andrew T Bender, Joseph A Beavo
Feb 20, 2007·Circulation Research·Kenji Omori, Jun Kotera
Apr 4, 2008·Journal of the American Society of Nephrology : JASN·Baoxue YangA S Verkman
Jun 4, 2008·Seminars in Nephrology·Vicente E Torres

❮ Previous
Next ❯

Citations

May 9, 2013·Future Medicinal Chemistry·Chatchai Muanprasat, Varanuj Chatsudthipong
Dec 17, 2009·Current Opinion in Gastroenterology·Jayashree VenkatasubramanianMrinalini C Rao
Sep 17, 2015·Journal of the American Society of Nephrology : JASN·Hong YeVicente E Torres
Nov 20, 2009·Kidney International·Xiaofang WangVicente E Torres
Mar 12, 2010·Advances in Chronic Kidney Disease·Vicente E Torres
Sep 3, 2013·Current Opinion in Pharmacology·Jay R Thiagarajah, A S Verkman
Jan 16, 2019·Journal of Cellular Physiology·Talieh MalekshahabiReza Moghadasali
Dec 18, 2013·Journal of the American Society of Nephrology : JASN·Vicente E Torres, Peter C Harris
Jun 13, 2009·Journal of the American Society of Nephrology : JASN·Vicente E Torres
Dec 26, 2018·Clinical Kidney Journal·Roman-Ulrich Müller, Thomas Benzing
Apr 27, 2020·Cellular Signalling·Caroline R SussmanVicente E Torres

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.